Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Pharming (PHAR) EPS (Basic) (2019 - 2024)

Historic EPS (Basic) for Pharming (PHAR) over the last 6 years, with Q4 2024 value amounting to -$45.4 million.

  • Pharming's EPS (Basic) changed N/A to -$45.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$45.4 million, marking a year-over-year change of. This contributed to the annual value of -$46.6 million for FY2024, which is 29128874990000.0% down from last year.
  • Latest data reveals that Pharming reported EPS (Basic) of -$45.4 million as of Q4 2024.
  • In the past 5 years, Pharming's EPS (Basic) ranged from a high of $624131.4 in Q4 2021 and a low of -$108.0 million during Q2 2023
  • For the 5-year period, Pharming's EPS (Basic) averaged around -$20.5 million, with its median value being -$7.9 million (2021).
  • In the last 5 years, Pharming's EPS (Basic) soared by 48304.11% in 2021 and then tumbled by 28286231.64% in 2022.
  • Pharming's EPS (Basic) (Quarter) stood at -$162941.1 in 2020, then surged by 483.04% to $624131.4 in 2021, then tumbled by 1619.1% to -$9.5 million in 2022, then tumbled by 339.17% to -$41.6 million in 2023, then decreased by 9.12% to -$45.4 million in 2024.
  • Its EPS (Basic) stands at -$45.4 million for Q4 2024, versus -$41.6 million for Q3 2023 and -$108.0 million for Q2 2023.